Press Center

Lidings announces the launch of a new Regulatory Practice. The practice will be headed by the firm's Counsel Julia Kuzmenko.

The creation of the new practice continues the development of Lidings' industry expertise and responds to the growing demand from businesses for comprehensive support amid increasingly complex government regulation and new mandatory requirements.

The Lidings team, led by Managing Partner Boris Malakhov and including Senior Associate Vladislav Ryabov, Associate Ivan Vasiliev, and Junior Associate Alena Troitskaya, advised the client in the dispute concerning intellectual property and brand protection in the Russian Federation.

The new review of the most notable patents disputes in Life Sciences in EAEU and CIS.

• pdf, 13.31 Mb

On the threshold of its 20th anniversary, Lidings is implementing the next stage in the evolution of its management model.

Lidings takes high positions in the new rating of the leading legal advisors in Russia based on the analytical research held annually by the “Kommersant” newspaper. In 2026 the firm is ranked among the TOP leading legal advisors in Russia. 

A change of managing partner at a law firm is rarely just a personnel decision – more often, it is a test of the sustainability of the business model and the maturity of the partnership. Lidings partners Andrey Zelenin and his successor as managing partner, Boris Malakhov, argue that their transition was neither a crisis nor a reboot, but rather a confirmation of the viability of the chosen governance structure – one that maintains trust within the team and carefully adapts to a changing market.

April 9^th,2026 annual conference Pharmaceuticals – 2026: Legal Issues will take place in Moscow organized by Pravo.ru. Lidings lawyers take an active part in the event’s program.

As a strategic partner of the conference, we aimed to make the program rich and actual. Together with pharmaceutical industry experts and lawyers, we will discuss how the market has changed in 2025 and what awaits us in 2026.

India has long and firmly established itself as the ‘pharmacy of the world’, as the country produces a fifth of all generics and provides affordable medicines to millions of people across the globe. However, India is now transitioning from copying innovative molecules to creating them. Amid the restructuring of global supply chains and strategic rapprochement with Russia, India is becoming both a battleground for fierce patent wars and a unique laboratory for joint research. How can Russian pharmaceutical companies establish intellectual property protection in a jurisdiction where the balance between the interests of pharmaceutical giants and the affordability of medicines for the population is enshrined in law? Boris Malakhov and Natalya Thotahewage analyse the key features of patenting and the prospects for technological alliances between Moscow and Delhi.